Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-B oncogenesis

Oncogene

Volumn 29, Issue 35, 2010, Pages 4925-4937

  Bose Jr , H R ^a   Liss, A S ^a,b   Tiwari, R ^a   Kralova, J ^a,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

AP 1; MAPK; oncogenesis; Ras; Rel NF kB; v Rel

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; HETERODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RAF PROTEIN; RAS PROTEIN; RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR REL; DNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P21;

ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; DIMERIZATION; EMBRYO; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MUTANT; ONCOGENE; ONCOGENE C FOS; ONCOGENE C JUN; ONCOGENE FRA 2; ONCOGENE V REL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; ANIMAL; CELL CULTURE; CELL LINE; CHICK EMBRYO; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ACTIVATING TRANSCRIPTION FACTOR 2; ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CHICK EMBRYO; DNA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; ONCOGENE PROTEINS V-REL; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS P21(RAS); RAF KINASES; TRANSCRIPTION FACTOR AP-1;

EID: 77956341456     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.239     Document Type: Article

References (46)

1. Aggarwal BB. (2004). Nuclear factor-kB: the enemy within. Cancer Cell 6: 203-208.
2. Angel P, Hattori K, Smeal T, Karin M. (1988). The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55: 875-885.
3. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ et al. (1987). Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49: 729-739.
4. Bhoumik A, Fichtman B, Derossi C, Breitwieser W, Kluger HM, Davis S et al. (2008). Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci USA 105: 1674-1679.
5. Bonizzi G, Karin M. (2004). The two NF-kB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
6. Breitwieser W, Lyons S, Flenniken AM, Ashton G, Bruder G, Willington M et al. (2007). Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev 21: 2069-2082.
7. Chaudhary A, King WG, Mattaliano MD, Frost JA, Diaz B, Morrison DK et al. (2000). Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr Biol 10: 551-554.
8. Chen FE, Ghosh G. (1999). Regulation of DNA binding by Rel/NF-kB transcription factors: structural views. Oncogene 18: 6845-6852.
9. Chin M, Herscovitch M, Zhang N, Waxman DJ, Gilmore TD. (2009). Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene 28: 2100-2111.
10. Chong H, Lee J, Guan KL. (2001). Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20: 3716-3727.
11. Courtois G, Gilmore TD. (2006). Mutations in the NF-kB signaling pathway: implications for human disease. Oncogene 25: 6831-6843.
12. Das RM, Van Hateren NJ, Howell GR, Farrell ER, Bangs FK, Porteous VC et al. (2006). A robust system for RNA interference in the chicken using a modified microRNA operon. Dev Biol 294: 554-563.
13. Dyer RB, Herzog NK. (1995). Isolation of intact nuclei for nuclear extract preparation from a fragile B-lymphocyte cell line. Bio-techniques 19: 192-195.
14. Ewert D, Duhadaway J. (1999). Inhibition of apoptosis by Marek0s disease viruses. Acta Virol 43: 133-135.
15. Fujii M, Minamino T, Nomura M, Miyamoto K, Tanaka J, Seiki M. (1997). v-Rel activates the proto-oncogene c-jun promoter: a correlation with its transforming activity. Leukemia 11(Suppl 3): 402-404.
16. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T et al. (2004). NF-kB and AP-1 connection: mechanism of NF-kB-dependent regulation of AP-1 activity. Mol Cell Biol 24: 7806-7819.
17. Gilmore TD. (1999). Multiple mutations contribute to the oncogeni-city of the retroviral oncoprotein v-Rel. Oncogene 18: 6925-6937.
18. Hai T, Curran T. (1991). Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 88: 3720-3724.
19. Hess J, Angel P, Schorpp-Kistner M. (2004). AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973.
20. Howe LR, Marshall CJ. (1993). Identification of amino acids in p21ras involved in exchange factor interaction. Oncogene 8: 2583-2590.
21. Hrdlickova R, Nehyba J, Bose Jr HR.. (2001). Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibro-blasts. Mol Cell Biol 21: 6369-6386.
22. Hrdlickova R, Nehyba J, Humphries EH. (1994). v-Rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-Rel. J Virol 68: 308-319.
23. Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. (2002). The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kB signal transduc-tion pathway. Oncogene 21: 8759-8768.
24. Karin M, Liu Z, Zandi E. (1997). AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246.
25. Kralova J, Liss AS, Bargmann W, Bose Jr HR. (1998). AP-1 factors play an important role in transformation induced by the v-rel oncogene. Mol Cell Biol 18: 2997-3009.
26. Lewis JS, Vijayanathan V, Thomas TJ, Pestell RG, Albanese C, Gallo MA et al. (2005). Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2. Oncol Res 15: 113-128.
27. Liss AS, Bose HR. (2008). Encyclopedia of Virology In: Mahy BWJ and Van Regenmortel MHV (eds). pp 412-419.
28. Liss AS, Bose Jr HR. (2002). Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation. J Virol 76: 4928-4939.
29. Luo J, Manning BD, Cantley LC. (2003). Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262.
30. Maekawa T, Shinagawa T, Sano Y, Sakuma T, Nomura S, Nagasaki K et al. (2007). Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol 27: 1730-1744.
31. Majid SM, Liss AS, You M, Bose HR. (2006). The suppressionf of SH3BGRL is important for v-Rel-mediated transformation. Oncogene 25: 756-768.
32. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F et al. (2002). Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kB. EMBO J 21: 4104-4113.
33. Mathas S, Johrens K, Joos S, Lietz A, Hummel F, JanzMet al. (2005). Elevated NF-kB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 106: 4287-4293.
34. Minden A, Lin A, Claret FX, Abo A, Karin M. (1995). Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81: 1147-1157.
35. Morton S, Davis RJ, Cohen P. (2004). Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett 572: 177-183.
36. Nehyba J, Hrdlickova R, Bose Jr HR.. (1997). Differences in kB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein. Oncogene 14: 2881-2897.
37. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX et al. (2005). JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 18: 1365-1370.
38. Rayet B, Gelinas C. (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18: 6938-6947.
39. Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R et al. (2006). The p38 transduction pathway in prostatic neoplasia. J Pathol 208: 401-407.
40. Robbins DJ, Cheng M, Zhen E, Vanderbilt CA, Feig LA, Cobb MH. (1992). Evidence for a Ras-dependent extracellular signal-regulated protein kinase (ERK) cascade. Proc Natl Acad Sci USA 89: 6924-6928.
41. Shaulian E. (2010). AP-1-The Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal 22: 894-899.
42. Stephens RM, Rice NR, Hiebsch RR, Bose Jr HR., Gilden RV. (1983). Nucleotide sequence of v-rel: the oncogene of reticuloendotheliosis virus. Proc Natl Acad Sci USA 80: 6229-6233.
43. Sun H, King AJ, Diaz HB, Marshall MS. (2000). Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidyl-inositol 3-kinase, Cdc42/Rac and Pak. Curr Biol 10: 281-284.
44. van Dam H, Castellazzi M. (2001). Distinct roles of Jun:Fos and Jun:ATF dimers in oncogenesis. Oncogene 20: 2453-2464.
45. Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, Gorgoulis V, Zoumpourlis V. (2008). The role of ATF-2 in oncogenesis. Bioessays 30: 314-327.
46. Zoumpourlis V, Papassava P, Linardopoulos S, Gillespie D, Balmain A, Pintzas A. (2000). High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 19: 4011-4021.